tacrolimus has been researched along with Acne-Vulgaris* in 7 studies
7 other study(ies) available for tacrolimus and Acne-Vulgaris
Article | Year |
---|---|
Topical tacrolimus for acne-related macular erythema to prevent atrophic scarring.
Topics: Acne Vulgaris; Atrophy; Cicatrix; Connective Tissue Diseases; Erythema; Humans; Tacrolimus; Treatment Outcome | 2022 |
Successful Treatment of PAPA Syndrome with Dual Adalimumab and Tacrolimus Therapy.
Topics: Acne Vulgaris; Adalimumab; Arthritis, Infectious; Child; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Pyoderma Gangrenosum; Tacrolimus; Treatment Outcome | 2019 |
Facial acne during topical pimecrolimus therapy for vitiligo.
Topics: Acne Vulgaris; Adolescent; Dermatologic Agents; Drug Eruptions; Humans; Male; Tacrolimus; Vitiligo | 2009 |
Focal acne during topical tacrolimus therapy for vitiligo.
Topics: Acne Vulgaris; Adolescent; Facial Dermatoses; Female; Humans; Immunosuppressive Agents; Tacrolimus; Vitiligo | 2007 |
Randomized controlled trial of pimecrolimus 1% cream for treatment of facial acne vulgaris.
Topics: Acne Vulgaris; Adolescent; Chemistry, Pharmaceutical; Child; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Pilot Projects; Tacrolimus | 2005 |
Are we starting to induce skin cancer in order to avoid topical steroids?
Topics: Acne Vulgaris; Animals; Child; Humans; Immunosuppressive Agents; Mice; Mice, Hairless; Skin Neoplasms; Steroids; Tacrolimus | 2005 |
Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment.
Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment.. Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments. Within 2 to 3 weeks of initially effective and well-tolerated treatment, 3 patients with a history of rosacea and 1 with a history of acne experienced sudden worsening with pustular rosaceiform lesions. Biopsy revealed an abundance of Demodex mites in 2 of these patients. In 1 patient with eyelid eczema, rosaceiform periocular dermatitis gradually appeared after 3 weeks of treatment. In 1 patient with atopic dermatitis, telangiectatic and papular rosacea insidiously appeared after 5 months of treatment.. Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with tacrolimus ointment is heterogeneous. A variety of factors, such as vasoactive properties of tacrolimus, proliferation of Demodex due to local immunosuppression, and the occlusive properties of the ointment, may be involved in the observed phenomena. Future studies are needed to identify individual risk factors. Topics: Acne Vulgaris; Administration, Topical; Adult; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ointments; Risk Assessment; Rosacea; Sampling Studies; Severity of Illness Index; Tacrolimus | 2004 |